(HealthDay News) — Measuring the walking speed of multiple sclerosis patients can help doctors assess progression of the disease and the severity of disability, a new study suggests.
In people with multiple sclerosis (MS), the immune system damages the protective myelin sheath around the body’s nerves.
“We already know that the timed 25-foot walk test is a meaningful way to measure disability in MS,” study author Dr. Myla Goldman, of the University of Virginia in Charlottesville, said in a news release from the American Academy of Neurology. “Our study builds on that research by providing a clearer idea of how walk time can provide information about how a person’s disease progression and disability impacts their everyday activities and real-world function.”
via Walking Speed a Good Gauge of MS Disability, Study Says.
(HealthDay News) — Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.
The errant behavior of the cells in question — known as "B cells" — is viewed as key to the development of this chronic and disabling nervous system disease, commonly called MS.
The new therapy’s potential is only in the early stages of exploration, cautions an international study team comprised of researchers from the United States, Canada, Switzerland and the Netherlands, in the report published in the Nov. 1 online edition of The Lancet.
via New Multiple Sclerosis Therapy Promising in Early Trial.
HealthDay News — A new oral medication for the treatment of multiple sclerosis MS shows promise in slowing disease progression, limiting brain atrophy and reducing MS relapses, a recently completed two-year clinical trial demonstrates.The findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.The study found that to date, the new drug appears to be both safe and well-tolerated. If the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.
via New Pill for MS Shows Promise in Clinical Trial.
(AFP) – German pharmaceutical group Merck KgaA said Wednesday that the US Food and Drug Administration (FDA) has refused to approve use of its multiple sclerosis treatment Cladribine.
The FDA declined to approve the drug "in its present form" and asked Merck to "provide an improved understanding of the safety risks and the overall benefit-risk profile," either through additional analyses or studies.
via Merck says US rejects its MS drug – Yahoo! News.